Trial · NCT07585734
Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
NCT07585734, Phase 1, Phase 2, Withdrawn, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia. Trials, record NCT07585734. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07585734
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia
- NCT number
- NCT07585734
- Status
- Withdrawn
- Phases
- Phase 1, Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- T-ALL
- Interventions
- Pediatric-Inspired Chemotherapy Regimen
- First posted
- 2026-05-14
- Last updated
- 2026-05-14
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To determine the maximum tolerated dose (MTD) of CM313 in combination with chemotherapy. | 6 weeks after induction therapy | The CM313 combination chemotherapy regimen is divided into three dose levels: dose level -1, dose level 0, and dose level +1. |
| Primary | MRD-negative complete remission (CR) rate by flow cytometry following induction therapy. | Up to approximately eight weeks | Among those who have achieved CR after induction therapy, proportion of patients who is MRD-negative |
| Secondary | The ratio of Complete remission (CR)/CR with partial hematologic recovery (CRh)/CR with incomplete hematologic recovery (CRi) | Six weeks after therapy | The ratio of patients achieved CR/CRh/CRi after therapy. |
| Secondary | Rate of conversion from MRD+to MRD- by Next-generation sequencing (NGS) after induction therapy | 30-days after induction therapy | Next-generation sequencing (NGS) is a high-throughput sequencing methodology and is a process by which small fragments of DNA are sequenced in parallel multiple times |
| Secondary | overall survival | up to 2 years after the date of the last enrolled participants | The interval from the date of enrollment to the date of death or the date of last follow-up, whichever occurred first |
| Secondary | Relapse free survival | up to 2 years after the date of the last enrolled participants | This outcome analyzes patients achieved CR after therapy. |
| Secondary | Event-free survival (EFS) | up to 2 years after the date of the last enrolled participants | This outcome analyzes patients who received the therapy. |
| Secondary | Cumulative incidence of relapse (CIR) | up to 2 years after therapy | Cumulative incidence of relapse within 2 years post-treatment |
| Secondary | 30-day mortality | within 30 days from the start of the trial | Percentage of patients who died within 30 days from enrollment |
| Secondary | 60-day mortality | within 60 days from the start of the trial | Percentage of patients who died within 60 days from enrollment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07585734
GET https://conductscience.org/api/trials/v1/NCT07585734/registered